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ABSTRACT
Of 233 erythromycin-resistant pneumococcal iso-
lates collected in Belgium in 1999–2000, 89.7%
carried the erm(B) gene, 6% the mef(A) gene, and
3.5% erm(B) plus mef(A). Two isolates contained
neither erm(B) nor mef(A); one contained an
erm(A) subclass erm(TR) gene, while the other
contained an A2058G mutation in domain V of
the 23S rRNA gene. Of 209 erm(B)-positive iso-
lates, 191 had clindamycin MICs > 16 mg ⁄L and
18 had MICs £ 16 mg ⁄L. Mef(A)-positive isolates
all displayed the M resistance phenotype. Telith-
romycin remained active against erythromycin-
resistant isolates, with the highest telithromycin
MIC50 being found in mef(A)-positive isolates. No
difference in the prevalence of different resistance
mechanisms was observed compared to isolates
collected in 1995–1997.
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Erythromycin resistance in pneumococcal isolates
from Belgium increased from 5.5% in 1986 to 37%
in 2003 [1]. Macrolides are still used extensively in
Belgium, despite a consensus that they are not the
ﬁrst-choice therapy for respiratory tract infections
in adults. As the data suggest that macrolides
may drive b-lactam resistance, it remains import-
ant to monitor macrolide resistance [2].
Pneumococcal macrolide resistance can be
caused by erm(B) (erythromycin ribosome methy-
lase)-encoded methylation of a residue in the 23S
rRNA [3]. Phenotypically, this results in the MLSB
resistance phenotype, with resistance to all
macrolides plus lincosamides and streptogramin
B antibiotics. An alternative resistance mechanism
involves mef(A) (macrolide efﬂux), resulting in
M-type resistance to 14- and 15-membered macro-
lides, but not to 16-membered macrolides, lincos-
amides or streptogramin B antibiotics. The
simultaneous presence of mef(A) and erm(B) has
been reported [4], while other reports have
described mutations in regions V and II of the
23S rRNA gene, and also in genes encoding
riboproteins L4 and L22. Resistance phenotypes
correlating with these mutations may vary [5,6].
Two studies examined erythromycin resistance
in pneumococci collected from Belgium in
1995–1997, and showed that resistance was asso-
ciated predominantly with erm(B)- and rare
mef(A)-positive isolates [7,8]. In the present study,
637 Streptococcus pneumoniae isolates obtained
from clinical samples (respiratory, blood, cere-
brospinal ﬂuid) in Belgium between October 1999
and February 2000 were investigated.
Antibiotic susceptibility was determined by
adding doubling dilutions (0.008–16 mg ⁄L) of
antibiotics to molten Mueller–Hinton agar (Oxoid,
Basingstoke, UK) supplemented with horse blood
5% v ⁄v. Multipoint inoculation was in duplicate,
with 104 CFU ⁄ spot, followed by incubation for
24 h at 36C in CO2 5% v ⁄ v. NCCLS breakpoints
were used for interpretation of the results. Anti-
biotics were provided by their respective manu-
facturers.
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Of the 637 isolates, 233 (36.6%) were erythro-
mycin-resistant (MIC ‡ 1 mg ⁄L). No intermedi-
ately resistant strains were found. All
erythromycin-resistant isolates were analysed
further by PCR. Following growth overnight on
blood agar in CO2 5% v ⁄v, single colonies were
grown in 5 mL of brain–heart infusion broth for
4.5 h, and this was followed by extraction of DNA
with Instagene matrix (Bio-Rad, Nazareth,
Belgium), as recommended by the manufacturer.
Primer sets for erm(B) and mef(A), and PCR
conditions, were as described previously [9–11],
with optimised magnesium concentrations of
2 mM for erm(B), and 4 mM for mef(A). Erythro-
mycin-susceptible and -resistant pneumococci of
known genotype (02J1095 for erm(B) and 02J1175
for mef(A); gifts of J. Sutcliffe, Pﬁzer, Groton, CT,
USA) were included as controls. Isolates without
erm(B) and mef(A), or isolates with both genes,
were retested. Detection of ribosomal mutations
and detection of erm(A) subclass erm(TR) were as
described previously [12,13]. Serotyping was by
capsular swelling with factor-speciﬁc antisera
(Statens Serum Institute, Copenhagen, Denmark).
Of the 233 resistant isolates, 209 (89.7%) had
the erm(B) gene only, and 14 (6%) had the mef(A)
gene only. Eight isolates had both erm(B) and
mef(A), while two isolates had neither erm(B) nor
mef(A). Erm(B)-positive isolates generally had
erythromycin and clindamycin MICs of
> 16 mg ⁄L (Table 1). Sixteen erm(B)-positive iso-
lates had telithromycin MICs of ‡ 1 mg ⁄L. How-
ever, agar dilution MICs obtained following
incubation in CO2 5% v ⁄ v tended to be one
two-fold dilution higher than those obtained by
the microdilution method [14]. Mef(A)-positive
isolates had lower erythromycin MICs and
remained susceptible to clindamycin. The erm(B)
plus mef(A)-positive isolates had erythromycin
and clindamycin MICs that were predominantly
> 16 mg ⁄L.
Of the two isolates that contained neither
erm(B) nor mef(A), one had an erm(A) subclass
erm(TR) gene, with an erythromycin MIC of
2 mg ⁄L, a clindamycin MIC of 0.12 mg ⁄L, and a
telithromycin MIC of 0.06 mg ⁄L. The erm(A)
subclass erm(TR) methylase has been described
mostly in Streptococcus pyogenes, but it has also
been reported in pneumococci from Greece and
Spain [15,16]. The erm(A) isolate in the present
study was from an elderly patient with chronic
obstructive pulmonary disease who had not
received treatment with macrolides. Apart from
a visit to Crete in 1993, the patient had not left
Belgium. The serogroup of this isolate (type 23)
was different from that in Greece (type 11a), but it
had a similar resistance phenotype. Pulsed-ﬁeld
gel electrophoresis also indicated that the isolate
was different from the Greek strain (data not
shown).
The second isolate that contained neither erm(B)
nor mef(A) had an A2058G mutation in domain V
of the 23S rRNA gene. This mutation was found
in all four copies of rrl. The isolate was resistant to
erythromycin and clindamycin (MICs > 16 mg ⁄L)
and had a telithromycin MIC of 0.25 mg ⁄L. This
isolate was from a patient with chronic obstruct-
ive pulmonary disease treated with b-lactams and
quinolones, but not macrolides or lincosamides.
The penicillin MIC was 1 mg ⁄L, and the levo-
ﬂoxacin MIC was 16 mg ⁄L. No recent journeys
abroad were recorded.
Of the erm(B)-positive isolates, 4.8% had a
penicillin MIC of 2 mg ⁄L, while 27.8% were
intermediately resistant. Of the mef(A)-positive
isolates, 15% were intermediately resistant to
penicillin. According to specimen type, erythro-
mycin resistance was found in 34.3% of isolates
from sputum or the lower respiratory tract (of
which 89% were erm(B)-positive), in 31.6% of
isolates from blood or cerebrospinal ﬂuid (93%
erm(B)-positive), and in 39.6% of isolates from
nose, sinus or throat samples (all erm(B)-positive).
Of isolates from middle ear ﬂuid samples, 54.5%
were erythromycin-resistant and all were erm(B)-
positive. Of 14 mef(A)-positive isolates, 12 were
from sputum or bronchial aspirates, and two were
from blood. Of eight erm(B) plus mef(A)-positive
isolates, ﬁve were from sputum or bronchial




MIC (mg ⁄L) distributionb
Antibiotica 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 > 16
erm(B) Ery 1 1 2 0 205c
Cli 3 4 4 3 1 1 1 1 191
Tel 17 78 62 12 14 10 6 10
mef(A) Ery 5 4 3 2
Cli 3 11
Tel 4 4 3 2 1
erm(B) +
mef(A)
Ery 1 0 0 7
Cli 1 1 0 0 0 0 0 0 6
Tel 2 1 2 1 0 0 2
aEry, erythromycin; Cli, clindamycin; Tel, telithromycin.
bNumber of isolates for each MIC value.
cMIC50 and MIC90 values are in bold type.
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aspirates, two were from blood, and one was from
middle ear ﬂuid.
Of 371 pneumococcal isolates from the northern
region of Belgium (Flanders), 28% were erythro-
mycin-resistant. Of these, 81.7% were erm(B)-
positive and 11.5% mef(A)-positive. In contrast, in
the southern part of Belgium (Wallonia), 49.5% of
208 pneumococcal isolates were erythromycin-
resistant, but 95.1% were erm(B)-positive and
1.9% mef(A)-positive, while in the capital region
(Brussels), 43.3% of 60 isolates were erythromy-
cin-resistant, with 92.3% erm(B)-positive and no
mef(A)-positive isolates. A similar regional dis-
parity has been found in Belgium among macro-
lide-resistance mechanisms for S. pyogenes [1].
However, the use of macrolides is greater in
Wallonia, with a consumption in the year 2000 of
3.42 deﬁned daily doses ⁄ 1000 inhabitants, com-
pared to 2.85 deﬁned daily doses ⁄ 1000 inhabit-
ants in Flanders (IMS Health, Brussels, Belgium).
Although 34% of erythromycin-resistant isolates
were from children aged < 5 years, only two of 14
mef(A)-positive isolates were from this age group,
with erm(B)-positive isolates accounting for 97.6%
of erythromycin-resistant isolates in this group.
Taking into account the differences in dosages
between children and adults, approximately three
times more macrolides are prescribed for children
than for adults. These data suggest a link between
high macrolide consumption and the selection of
erm(B)-positive rather than mef(A)-positive
strains.
MLSB cross-resistance to macrolides and lin-
cosamides was predominant. Since clindamycin
can be an inducer of erm(B) in streptococci,
inducible MLSB resistance cannot be distin-
guished from constitutive resistance on the sole
basis of elevated MICs of erythromycin and
clindamycin. It has been suggested that constitu-
tive MLSB resistance is found infrequently in
pneumococci [17]. The results of the present study
indicate that erm(B) remains the predominant
macrolide-resistance mechanism among pneumo-
cocci in Belgium.
REFERENCES
1. National Institute for Public Health. Data from the refer-
ence laboratories, Belgium 2004. http://www.iph.fgov.be.
2. Garcia-ReyC,Aguilar L, Baquero F et al. Importance of local
variations in antibiotic consumption and geographical dif-
ferences of erythromycin and penicillin resistance in Strep-
tococcus pneumoniae. J Clin Microbiol 2002; 40: 159–164.
3. Leclercq R, Courvalin P. Resistance to macrolides and
related antibiotics in Streptococcus pneumoniae. Antimicrob
Agents Chemother 2002; 46: 2727–2734.
4. Farrell DJ, Morrissey I, Bakker S et al. Molecular charac-
terization of macrolide resistance mechanisms among
Streptococcus pneumoniae and Streptococcus pyogenes isolated
from the Protekt 1999–2000 study. J Antimicrob Chemother
2002; 45(suppl 1): 39–47.
5. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new
mechanisms of macrolide resistance in clinical strains of
Streptococcus pneumoniae from Eastern Europe and North
America. Antimicrob Agents Chemother 2000; 44: 3395–3401.
6. Doktor SZ, Shortridge VD, Beyer JM et al. Epidemiology of
macrolide and ⁄ or lincosamide resistant Streptococcus
pneumoniae clinical isolates with ribosomal mutations.
Diagn Microbiol Infect Dis 2004; 49: 47–52.
7. Lagrou K, Peetermans WE, Verhaegen J et al. Macrolide
resistance in Belgian Streptococcus pneumoniae. J Antimicrob
Chemother 2000; 45: 119–121.
8. Descheemaeker P, Chapelle S, Lammens C et al.Macrolide
resistance and erythromycin resistance determinants
among Belgian Streptococcus pyogenes and Streptococcus
pneumoniae isolates. J Antimicrob Chemother 2000; 45: 167–
173.
9. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus
pneumoniae and Streptococcus pyogenes resistant to macro-
lides but sensitive to clindamycin: a common resistance
pattern mediated by an efﬂux system. Antimicrob Agents
Chemother 1996; 40: 1817–1824.
10. Shortridge VD, Flamm RK, Ramer N et al. Novel mecha-
nisms of macrolide resistance in Streptococcus pneumoniae.
Diagn Microbiol Infect Dis 1996; 26: 73–78.
11. Sutcliffe J, Grebe T, Tait-Kamradt A et al. Detection of
erythromycin-resistant determinants by PCR. Antimicrob
Agents Chemother 1996; 40: 2562–2566.
12. Canu A, Malbruny B, Coquemont M et al. Diversity of
ribosomal mutations conferring resistance to macrolides,
clindamycin, streptogramin, and telithromycin in Strepto-
coccus pneumoniae. Antimicrob Agents Chemother 2002; 46:
125–131.
13. Angot P, Vergnaud M, Auzou M et al. Macrolide resist-
ance phenotypes and genotypes in French clinical isolates
of Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis
2000; 19: 755–758.
14. Davies TA, Kelly LM, Jacobs MR et al. Antipneumococcal
activity of telithromycin by agar dilution, microdilution, E
test, and disk diffusion methodologies. J Clin Microbiol
2000; 38: 1444–1448.
15. Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A et al.
Identiﬁcation of an erm (A) erythromycin resistance
methylase gene in Streptococcus pneumoniae isolated in
Greece. Antimicrob Agents Chemother 2001; 45: 342–344.
16. Betriu C, Redondo M, Palau ML et al. Comparative activ-
ities of linezolid, quinupristin–dalfopristin, moxiﬂoxacin
and trovaﬂoxacin against erythromycin-susceptible and -
resistant streptococci. Antimicrob Agents Chemother 2000;
44: 1838–1841.
17. Rosato A, Vicarini H, Leclercq R. Inducible or constitutive
expression of resistance in clinical isolates of streptococci
and enterococci cross-resistant to erythromycin and lin-
comycin. J Antimicrob Chemother 1999; 43: 559–562.
334 Clinical Microbiology and Infection, Volume 11 Number 4, April 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 326–340
